Jun 4 2010
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that two scientific abstracts on the activity of tranilast against key components of gout - high serum uric acid levels and monosodium urate crystal-induced inflammation - have been accepted for The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology, to be held in Rome, Italy, June 16-19, 2010.
EULAR 2010 Abstracts on Tranilast:
EULAR Abstract #SAT 0369
Tranilast, a novel, potential treatment for the chronic management of hyperuricemia in patients with gout, reduces serum uric acid (SUA) in healthy subjects.
Poster: Saturday, June 19, 2010, 10:15 AM: Fiera Roma- Poster Area in Hall 5
EULAR Abstract #AB 0054
Tranilast suppresses inflammation induced by monosodium urate (MSU) crystals in vivo.
Abstract only.
Abstracts are available on the League's website: www.eular.org.
(https://b-com.mci-group.com/AbstractList/EULAR10.aspx)
Nuon Therapeutics' lead product, NU1618, is a proprietary combination of tranilast and allupurinol currently in phase 2 development for the treatment of hyperuricemia in patients with gout. Topline data from a completed proof-of-principle, phase 2a study of NU1618 will be released later this month.
Genetics identified as key factor in gout development